Dendreon Corp (NASDAQ:DNDN)
CAPS Rating:
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Recs
Talk about playing with fire. Every time Dendreon dips, I wonder if there's another upward run left or if this is the swirl. I've been sucked into as many swirls as anyone, but on CAPS I make my parameters and stick to my guns. The burn is still obscene, the debt is atrocious, but there's 500M in cash as of the end of Q2 which gives the company at least a year to pull rabbits out of their hat. The only question is, will the rabbit pop out at a share price of 6 or 2?